Literature DB >> 9366321

Rapid detection of bladder cancer: a comparative study of point of care tests.

B Johnston1, A Morales, L Emerson, M Lundie.   

Abstract

PURPOSE: We assessed sensitivity, specificity, accuracy, positive predictive value and negative predictive value of the bladder tumor antigen (Bard BTA), fibrinogen/fibrin degradation products (AuraTek FDP), urinary cytology and hemoglobin dipstick tests in the urine of patients presenting to a urology clinic.
MATERIALS AND METHODS: A total of 130 patients (60 with bladder cancer) provided a urine sample, which was divided into appropriate aliquots for each of the tests cited above. The endoscopist, pathologist, cytologist and the person performing the BTA/FDP/hemoglobin dipstick were blinded as to the results of the other tests, and the tests were read independently by a second blinded evaluator.
RESULTS: Comparative results demonstrate a clear superiority of FDP in sensitivity (81%) and overall accuracy in bladder cancer detection (p = 0.0001) while cytology and BTA were marginally better than FDP in specificity.
CONCLUSIONS: The anticipated lack of specificity of the hemoglobin dipstick was confirmed as well as the inadequacy of urinary cytology, particularly in the well differentiated tumors. Our findings with BTA were disappointing. The superiority of the FDP, first demonstrated here, was particularly striking in its ability to detect even well differentiated tumors. The simplicity and significantly better overall performance of FDP make it a reliable test for detection of transitional cell carcinoma of the bladder and a potential alternative to urinary cytology with important implications for clinical practice and health economics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366321     DOI: 10.1016/s0022-5347(01)68166-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Time to abandon testing for microscopic haematuria in adults?

Authors:  Per-Uno Malmström
Journal:  BMJ       Date:  2003-04-12

Review 2.  Early bladder cancer: concept, diagnosis, and management.

Authors:  Hiroshi Kitamura; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.402

3.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

4.  Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.

Authors:  D Chao; S J Freedland; A J Pantuck; A Zisman; A S Belldegrun
Journal:  Rev Urol       Date:  2001

5.  A pilot study of urinary microRNA as a biomarker for urothelial cancer.

Authors:  Jaime Snowdon; Sandy Boag; Harriet Feilotter; Jason Izard; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

6.  Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Authors:  Shahrokh F Shariat; Jose A Karam; Yair Lotan; Pierre I Karakiewizc
Journal:  Rev Urol       Date:  2008

Review 7.  Bladder tumor markers: need, nature and application. 2. Tumor and tumor-associated antigens.

Authors:  M M Kirollos; S McDermott; R A Bradbrook
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 8.  Alternatives to cytology in the management of non-muscle invasive bladder cancer.

Authors:  Gilad E Amiel; Tung Shu; Seth P Lerner
Journal:  Curr Treat Options Oncol       Date:  2004-10

Review 9.  [Non-invasive urinary diagnosis of bladder cancer. What do we know?].

Authors:  I Kausch; A Böhle
Journal:  Urologe A       Date:  2003-04-11       Impact factor: 0.639

10.  Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up?

Authors:  G Nabi; D Greene; M O O'Donnell; M O Donnel
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.